Tandem Diabetes Care Shares Gain 9.7% on FDA OK
11 Luglio 2023 - 5:01PM
Dow Jones News
By Ben Glickman
Shares of Tandem Diabetes Care climbed Tuesday after the company
said the U.S. Food and Drug Administration cleared its Tandem Mobi
insulin pump.
The stock was up 9.7% to $27.35 in mid-morning trading. Shares
are down 39% year to date.
The San Diego-based diabetes technology company said its
miniature insulin pump had received clearance for people with
diabetes age 6 and older, and was the world's smallest durable
insulin-delivery system.
Tandem said it expects a limited release of the Tandem Mobi in
late 2023 and a full commercial release by early 2024.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 11, 2023 10:46 ET (14:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Tandem Diabetes Care (NASDAQ:TNDM)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Tandem Diabetes Care (NASDAQ:TNDM)
Storico
Da Giu 2023 a Giu 2024